NAGIOS: RODERIC FUNCIONANDO

Soluble galectin-3 as a microenvironment-relevant immunoregulator with prognostic and predictive value in lung adenocarcinoma

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

Soluble galectin-3 as a microenvironment-relevant immunoregulator with prognostic and predictive value in lung adenocarcinoma

dc.contributor.author	Torres Martínez, Susana
dc.contributor.author	Calabuig Fariñas, Silvia
dc.contributor.author	Moreno Manuel, Andrea
dc.contributor.author	Bertolini, Giulia
dc.contributor.author	Herreros Pomares, Alejandro
dc.contributor.author	Escorihuela, Eva
dc.contributor.author	Duréndez Sáez, Elena
dc.contributor.author	Guijarro Jorge, Ricardo
dc.contributor.author	Blasco, Ana
dc.contributor.author	Roz, Luca
dc.contributor.author	Camps Herrero, Carlos
dc.contributor.author	Jantus Lewintre, Eloisa
dc.date.accessioned	2023-09-11T12:13:18Z
dc.date.available	2023-09-11T12:13:18Z
dc.date.issued	2023
dc.identifier.citation	Torres Martínez, Susana Calabuig Fariñas, Silvia Moreno Manuel, Andrea Bertolini, Giulia Herreros Pomares, Alejandro Escorihuela, Eva Duréndez Sáez, Elena Guijarro Jorge, Ricardo Blasco, Ana Roz, Luca Camps Herrero, Carlos Jantus Lewintre, Eloisa 2023 Soluble galectin-3 as a microenvironment-relevant immunoregulator with prognostic and predictive value in lung adenocarcinoma Molecular Oncology
dc.identifier.uri	https://hdl.handle.net/10550/89189
dc.description.abstract	Despite the success of therapies in lung cancer, more studies of new biomarkers for patient selection are urgently needed. The present study aims to analyze the role of galectin-3 (GAL-3) in the lung tumor microenvironment (TME) using tumorspheres as a model and explore its potential role as a predictive and prognostic biomarker in non-small cell lung cancer (NSCLC) patients. For in vitro studies, lung adenocarcinoma (LUAD) and lung squamous carcinoma (LUSC) primary cultures from early-stage patients and commercial cell lines were cultured, using tumorsphere-forming assays and adherent conditions for the control counterparts. We analyzed the pattern of secretion and expression of GAL-3 using reverse transcription-quantitative real-time PCR (RTqPCR), immunoblot, immunofluorescence, flow cytometry and immunoassay analysis. Our results using three-dimensional (3D) models of lung tumor cells revealed that soluble GAL-3 (sGAL-3) is highly expressed and secreted. To more accurately mimic the TME, a co-culture of tumorspheres and fibroblasts was used, revealing that GAL-3 could be important as an immunomodulatory molecule expressed and secreted in the TME, modulating immunosuppression through regulatory T cells (TREGS). In the translational phase, we confirmed that patients with high expression levels of GAL-3 had more TREGS, which suggests that tumors may be recruiting this population through GAL-3. Next, we evaluated levels of sGAL-3 before surgery in LUAD and LUSC patients, hypothesizing that sGAL-3 could be used as an independent prognostic biomarker for overall survival and relapse-free survival in early-stage LUAD patients. Additionally, levels of sGAL-3 at pretreatment and first response assessment from plasma to predict clinical outcomes in advanced LUAD and LUSC patients treated with first-line pembrolizumab were evaluated, further supporting that sGAL-3 has a high efficiency in predicting durable clinical response to pembrolizumab with an area under curve (AUC) of 0.801 (p=0.011). Moreover, high levels might predict decreased progression-free survival and overall survival to anti-PD-1 therapy, with sGAL-3 being a prognosis-independent biomarker for advanced LUAD.
dc.language.iso	eng
dc.relation.ispartof	Molecular Oncology, 2023
dc.subject	Càncer
dc.title	Soluble galectin-3 as a microenvironment-relevant immunoregulator with prognostic and predictive value in lung adenocarcinoma
dc.type	journal article
dc.date.updated	2023-09-11T12:13:19Z
dc.identifier.doi	10.1002/1878-0261.13505
dc.identifier.idgrec	161072
dc.rights.accessRights	open access